TaiCon Bio Announces Board Approval of Q1 2026 Consolidated Financial Report
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
TaiCon Bio's board of directors approved its consolidated financial report for the first quarter of 2026 on May 12, 2026. The company reported revenue of 308,435K but incurred a net loss of 142,242K.